Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Operating Margin: 2012-2025

Historic Operating Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -121.56%.

  • Enanta Pharmaceuticals' Operating Margin rose 8282.00% to -121.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -130.65%, marking a year-over-year increase of 4927.00%. This contributed to the annual value of -130.65% for FY2025, which is 4927.00% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Operating Margin of -121.56% as of Q3 2025, which was down 17.83% from -103.16% recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Margin peaked at -103.16% during Q2 2025, and registered a low of -221.70% during Q1 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Operating Margin averaged around -166.61%, with its median value being -164.32% (2025).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Operating Margin slumped by 10,453bps in 2021, and later surged by 8,282bps in 2025.
  • Enanta Pharmaceuticals' Operating Margin (Quarterly) stood at -109.99% in 2021, then slumped by 1,727bps to -127.25% in 2022, then crashed by 6,652bps to -193.78% in 2023, then skyrocketed by 5,496bps to -138.82% in 2024, then surged by 8,282bps to -121.56% in 2025.
  • Its Operating Margin stands at -121.56% for Q3 2025, versus -103.16% for Q2 2025 and -164.32% for Q1 2025.